Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
Novel rate-controlled fentanyl patch shows promise in phase I clinical trial
April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
.svg){kind=small}
